Entera Bio (ENTX) Interest Expenses (2019 - 2026)

Entera Bio (ENTX) has reported Interest Expenses for 8 consecutive years, with $72000.0 the latest figure, recorded in Q1 2026.

• Quarterly Interest Expenses rose 28.57% year-over-year to $72000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $345000.0 (down 21.41% YoY) and the FY2025 annual result came in at $23.0 million, up 10.0% from the prior year.
• Interest Expenses retreated to $72000.0 in Q1 2026 per ENTX's latest filing, from $109000.0 in the prior quarter.
• Over the last five years, Interest Expenses for ENTX reached as high as $19.5 million in Q4 2023 and fell as low as $32000.0 in Q3 2024.
• A 5-year average of $3.2 million and a median of $124000.0 in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses tumbled 99.4% — and 2025, when it jumped 312.5%.
• Year by year, Interest Expenses stood at $17.6 million in 2022, then grew by 10.35% to $19.5 million in 2023, then sank by 99.4% to $116000.0 in 2024, then fell by 6.03% to $109000.0 in 2025, then tumbled by 33.94% to $72000.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $72000.0, $109000.0, and $132000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.